Cancer Treatment
FDA Approves Injectable Form of Merck's Keytruda
The U.S. Food and Drug Administration has granted approval for an injectable version of Merck's blockbuster cancer drug Keytruda, marking a significant advancement in treatment options for patients with certain types of cancer. This subcutaneous formulation promises greater convenience over the traditional intravenous method, potentially improving patient adherence and reducing healthcare burdens. The decision, announced on September 19, 2025, underscores ongoing innovations in oncology amid rising demands for more accessible therapies.
MIT engineers stealth CAR-NK cells for cancer therapy
Reported by AI
Scientists from MIT and Harvard have developed engineered CAR-NK immune cells that evade the body's defenses to target cancer effectively. This advancement could enable off-the-shelf treatments available immediately after diagnosis, bypassing weeks of personalized cell production. The cells showed strong results in mouse tests, destroying most lymphoma cells without triggering severe side effects.
FDA Approves Subcutaneous Version of Merck's Keytruda
Reported by AI Fact checked
The U.S. Food and Drug Administration has approved Merck's Keytruda Qlex, a subcutaneous formulation of the cancer drug pembrolizumab, for use in adults across most solid tumor indications. Announced on September 19, 2025, this new injectable version offers a quicker administration time compared to the traditional intravenous method, potentially enhancing patient convenience and access to treatment. The approval highlights efforts to innovate drug delivery in oncology amid growing demands for efficient therapies.
EMA Panel Recommends Approval for Merck's Injectable Keytruda
A key committee of the European Medicines Agency has recommended approval for an injectable version of Merck's cancer drug Keytruda, paving the way for potential authorization across the European Union. This subcutaneous formulation aims to offer a more convenient alternative to intravenous administration for patients with various cancers. The recommendation, issued on September 19, 2025, follows positive clinical data and could enhance treatment accessibility in Europe.